IP Library Granted Patent US 8,399,647
Granted Patent B2
US 8,399,647 · App. 13/237,502 · Granted Mar 19, 2013

Alpha5-beta1 antibodies and their uses

Inventors: Steven L. Bender (Oceanside, CA); Gerald F. Casperson (Ballwin, MO); Dana D. Hu-Lowe (Encinitas, CA); Xin Jiang (San Diego, CA); Gang Li (San Diego, CA); Michael A. North (Rancho Santa Fe, CA); Jianying Wang (San Diego, CA); Grant Wickman (Glasgow, GB); Peter Brams (Sacramento, CA); Haichun Huang (Fremont, CA); Brigitte Devaux (Palo Alto, CA); Haibin Chen (Sunnyvale, CA); Dawn M. Tanamachi (Miltpitas, CA); Kristopher Toy (San Jose, CA); Lan Yang (Morgan Hill, CA); Tim W. Sproul (Livermore, CA); Mark Yamanaka (Pleasanton, CA)
Assignees: Pfizer Inc.; Bristol-Myers Squibb Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,399,647
App. No.
13/237,502
Granted
Mar 19, 2013
Kind
B2
Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.

Claims (14)

1. An isolated nucleic acid molecule encoding an antibody, or antigen-binding portion thereof, that binds to human integrin α5β1, wherein said antibody or antigen-binding portion comprises:

(a) a heavy chain CDR1 as set forth in SEQ ID NO:1;

(b) a heavy chain CDR2 as set forth in SEQ ID NO:2;

(c) a heavy chain CDR3 as set forth in SEQ ID NO:3;

(d) a light chain CDR1 as set forth in SEQ ID NO:4;

(e) a light chain CDR2 as set forth in SEQ ID NO:5; and

(f) a light chain CDR3 as set forth in SEQ ID NO:6.

2. The nucleic acid molecule of claim 1 , wherein said antibody or antigen-binding portion comprises a heavy chain variable region amino acid sequence as set forth in SEQ ID NO:7.

3. The nucleic acid molecule of claim 1 , wherein said antibody or antigen-binding portion comprises a light chain variable region amino acid sequence as set forth in SEQ ID NO:8.

4. The nucleic acid molecule of claim 1 , wherein said antibody or antigen-binding portion comprises a heavy chain variable region amino acid sequence as set forth in SEQ ID NO:7; and a light chain variable region amino acid sequence as set forth in SEQ ID NO:8.

5. The nucleic acid molecule of claim 1 , wherein said antibody comprises a heavy chain amino acid sequence as set forth in SEQ ID NO:9; and a light chain amino acid sequence as set forth in SEQ ID NO:10.

6. An isolated vector comprising the nucleic acid molecule of claim 1 .

7. An isolated host cell transformed with the vector of claim 6 .

8. A method for preparing an anti-α5β1 antibody or antigen-binding portion thereof, comprising culturing the host cell of claim 7 under conditions that result in production of the antibody or antigen-binding portion, and isolating the antibody or antigen-binding portion from the host cell or culture.

Continuity (4)
Continuation 12365638 · Feb 4, 2009
Provisional Application 61026207 · Feb 5, 2008
Provisional Application 61095429 · Sep 9, 2008
Related Publication 20120009622A1 · Jan 12, 2012